4.6 Article

Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib

期刊

ACS CHEMICAL BIOLOGY
卷 10, 期 9, 页码 2099-2107

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acschembio.5b00174

关键词

-

资金

  1. DFG (German Research Society) [PE 1605/2-1]
  2. Medical Research Council [MC_UU_12016/2, MC_U127070193] Funding Source: researchfish
  3. MRC [MC_U127070193, MC_UU_12016/2] Funding Source: UKRI

向作者/读者索取更多资源

In this study, we report on novel photoactivatable caged prodrugs of vemurafenib. This kinase inhibitor was the first approved drug for the personalized treatment of BRAF-mutated melanoma and showed impressive results in clinical studies. However, the occurrence of severe side effects and drug resistance illustrates the urgent need for innovative therapeutic approaches. To conquer these limitations, we implemented photoremovable protecting groups into vemurafenib. In general, this caging concept provides spatial and temporal control over the activation of molecules triggered by ultraviolet light. Thus, higher inhibitor concentrations in tumor tissues might be reached with less systemic effects. Our study describes the first development of caged vemurafenib prodrugs useful as pharmacological tools. We investigated their photochemical characteristics and photoactivation. In vitro evaluation proved the intended loss-of-function and the light-dependent recovery of efficacy in kinase and cellular assays. The reported vemurafenib photo prodrugs represent a powerful biological tool for novel pharmacological approaches in cancer research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据